Prognostic Value of CDX2 and Villin Expression in Advanced Stage Colorectal Carcinoma

Abstract

Objective: To determine the frequency of expression of CDX2 and Villin in a subsection of advanced stage primary colorectal cancers and detect its association with tumour differentiation, lymph node metastasis, invasion and survival. Study Design: A descriptive study. Place and Duration of Study: Ortadogu Private Hospital, Adana, Turkey, from January 2012 to March 2017. Methodology: Formalin-fixed, paraffin-embedded tissue specimens were obtained from 70 patients who underwent surgery for colorectal carcinoma. Inclusion criteria were patients who underwent surgery with stage 3 and stage 4 colorectal cancer. The exclusion criteria were patients who had recurrent colorectal cancer and/or accompanying cancer in another region. Immunohistochemical technique was used for the localisation of CDX2 and Villin in colorectal cancer tissues. The catagorical variables between the groups was analysed by using the Chi-square test or Fisher Exc. test. Overall survival time was defined as the years elapsed between date of after operation and death as a result of disease (or the last follow-up date). Overall survival was analysed using the Wald test, and the log-rank test was used to examine their relationship when different parameters were applied. The survival curve was plotted using the standard Kaplan-Meier methodology. Values of p <0.05 were considered statistically significant. Results: Both CDX2 and Villin had relation with gender (p=0.045, p=0.016), male and female expression of CDX2 was n=31 (67.4%), n=15 (32.6%), respectively and Villin was n=34 (68.0%), n=16 (32.0%), respectively; age (p=0.804, p=0.791), had no relation with tumor site (p=0.131, p=0.921) and histologic grade (p=0.209, p=0.579) and lymph node metastasis (p=0.063, p=0.392) and perineural invasion (p=0.476, p=0.053) and lymphovasculer invasion (p=0.080, p=0.791) and overall survival ( p=0.121, hep=0.059). Conclusion: CDX2 and Villin were not associated with any of the clinicopathologic parameters. Overall survival analysis also did not show a significant association with immunoexpression of these molecules and survival. CDX2 and Villin might not be useful as a prognostic factor in advanced stage colorectal carcinoma